Oktay Bozkurt1, Halit Karaca1, Ilhan Hacıbekiroglu2, Muhammed Ali Kaplan3, Yakup Duzkopru4, Mukremin Uysal5, Veli Berk6, Mevlude Inanc6, Ayse Ocak Duran1, Ersin Ozaslan1, Mahmut Ucar1, Metin Ozkan1. 1. a Department of Medical Oncology , Erciyes University Faculty of Medicine , Kayseri , Turkey. 2. b Department of Medical Oncology , Trakya University Faculty of Medicine , Edirne , Turkey. 3. c Department of Medical Oncology , Dicle University Faculty of Medicine , Diyarbakır , Turkey. 4. d Department of Internal Medicine , Dicle University Faculty of Medicine , Diyarbakır , Turkey. 5. e Department of Medical Oncology , Afyon Kocatepe University Faculty of Medicine , Turkey. 6. f Kayseri Training and Research Hospital , Medical Oncology Department , Turkey.
Abstract
BACKGROUND: The main goal of this study was to examine whether the occurrence of hypothyroidism during sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC) is associated with a better outcome. METHODS: The study enrolled 81 patients with pathologically proven mRCC who were treated with sunitinib between March 2008 and June 2013.Thyroid function evaluation comprised (free-thyroxine) FT4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Survival analysis was performed using the Kaplan-Meier method, and the differences among the groups were determined using the log-rank test. RESULTS: Hypothyroidism occurred in 30 (37%) of 81 patients within a median 3 months (range 1-18) of treatment initiation. There was a statistically significant correlation between the occurrence of hypothyroidism during treatment and the rate of objective remission (ORR) (hypothyroid patients vs euthyroid patients: 46.7 vs 13.7%, respectively; P = 0.001). Median progression-free survival (PFS) was 10 (95% CI 6.13-13.8) months in the euthyroid patients, and 17 (95% CI 9.33-24.6) months in the hypothyroid patients (P = 0.001). The median overall survival (OS) was 39 (95% CI 25.4-52.5) months in the hypothyroid patients and 20 (95% CI 14.7-25.2) months in the euthyroid patients (P = 0.019). CONCLUSIONS: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study.
BACKGROUND: The main goal of this study was to examine whether the occurrence of hypothyroidism during sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC) is associated with a better outcome. METHODS: The study enrolled 81 patients with pathologically proven mRCC who were treated with sunitinib between March 2008 and June 2013.Thyroid function evaluation comprised (free-thyroxine) FT4 and thyroid-stimulating hormone (TSH) before treatment and at day 1 of each 6-week cycle. Survival analysis was performed using the Kaplan-Meier method, and the differences among the groups were determined using the log-rank test. RESULTS:Hypothyroidism occurred in 30 (37%) of 81 patients within a median 3 months (range 1-18) of treatment initiation. There was a statistically significant correlation between the occurrence of hypothyroidism during treatment and the rate of objective remission (ORR) (hypothyroidpatients vs euthyroid patients: 46.7 vs 13.7%, respectively; P = 0.001). Median progression-free survival (PFS) was 10 (95% CI 6.13-13.8) months in the euthyroid patients, and 17 (95% CI 9.33-24.6) months in the hypothyroidpatients (P = 0.001). The median overall survival (OS) was 39 (95% CI 25.4-52.5) months in the hypothyroidpatients and 20 (95% CI 14.7-25.2) months in the euthyroid patients (P = 0.019). CONCLUSIONS: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study.
Authors: L Rizza; E Sbardella; D Gianfrilli; R Lauretta; M Tenuta; G Del Bene; F Longo; A Faggiano; A Lenzi; E Giannetta; C Pozza Journal: Endocrine Date: 2019-11-02 Impact factor: 3.633
Authors: Martin Pilskog; Leif Bostad; Reidunn J Edelmann; Lars A Akslen; Christian Beisland; Oddbjørn Straume Journal: J Pathol Clin Res Date: 2018-03-05
Authors: Ning Zhang; Weidong Jin; Shuangnan Zhou; Ju Dong Yang; William S Harmsen; Nasra H Giama; Nicha Wongjarupong; Julie K Heimbach; Kymberly D Watt; Harmeet Malhi; Terry M Therneau; Lewis R Roberts Journal: Cancer Med Date: 2018-11-19 Impact factor: 4.452